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Abstract: Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC] is 
an acyclic nucleoside analog approved since 1996 for clinical use in the treatment of 
cytomegalovirus (CMV) retinitis in AIDS patients. Cidofovir (CDV) has broad-spectrum 
activity against DNA viruses, including herpes-, adeno-, polyoma-, papilloma- and 
poxviruses. Among poxviruses, cidofovir has shown in vitro activity against orthopox 
[vaccinia, variola (smallpox), cowpox, monkeypox, camelpox, ectromelia], molluscipox 
[molluscum contagiosum] and parapox [orf] viruses. The anti-poxvirus activity of cidofovir 
in vivo has been shown in different models of infection when the compound was 
administered either intraperitoneal, intranasal (aerosolized) or topically. In humans, 
cidofovir has been successfully used for the treatment of recalcitrant molluscum 
contagiosum virus and orf virus in immunocompromised patients. CDV remains a 
reference compound against poxviruses and holds potential for the therapy and short-term 
prophylaxis of not only orthopox- but also parapox- and molluscipoxvirus infections. 
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1. Introduction  
The antiviral activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC, 
cidofovir, CDV) (Figure 1) against human cytomegalovirus (HCMV) and other DNA viruses was first 
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reported in 1986 [1]. In 1996, the intravenous form of CDV was licensed for clinical use, under the 
trade name of Vistide
®, for the systemic treatment of HCMV retinitis in AIDS patients.  
Figure 1. Chemical structure of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine 
(HPMPC (CDV)) and its natural nucleotide. 
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CDV is a close congener of HPMPA [(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine], 
which was the first acyclic nucleoside phosphonate (ANP) described with broad spectrum anti-DNA 
virus activity [1,2]. This compound can be considered a hybrid between acyclic nucleoside analogs, 
such as (S)-9-(2,3-dihydroxypropyl)adenine (DHPA), which was previously described as an ANP with 
broad-spectrum antiviral activity, and a phosphonate analog such as phosphonoformic acic (PFA) or 
phosphonoacetic acid (PAA). PMEA [2-(phosphonylmethoxyethyl)adenine, adefovir] was developed 
in parallel with HPMPA, whereas HPMPC was derived from HPMPA by simply substituting a 
pyrimidine (cytosine) for the purine (adenine) moiety. Further modifications of the acyclic   
side chain of HPMPA led to PMPA [2-(phosphonylmethoxypropyl)adenine] and PMPDAP   
[2-(phosphonylmethoxypropyl)2,6-diaminopurine]. PMEA displayed potent activity against 
retroviruses (while maintaining activity against herpes- and hepadnaviruses) while the antiviral activity 
of PMPA was restricted to retro- and hepadnaviruses. 
In regular nucleotides (or nucleoside phosphates), the phosphate group is attached through an ester 
bound (-P-O-C-) to the nucleoside. In the ANPs, the phosphate group—in a form of a phosphonate 
group—is already attached to the nucleoside analog, thus resulting in the formation of a 
phosphonomethyl ether (-P-C-O-), which unlike the phosphate ester linkage should resist any attack by 
esterases. Furthermore, the fact that a phosphonate group is built in the acyclic nucleoside skeleton 
turns these compounds in ANPs, and made it possible to bypass the first phosphorylation step. This 
first phosphorylation step, carried out by virus kinases, is necessary for the activation of the “classical” 
acyclic nucleoside analogs, such as acyclovir ACV and ganciclovir GCV. 
The discovery of ANPs represented a breakthrough in the treatment of DNA viruses and 
retroviruses. According to their activity spectrum, the first generation of ANPs can be classified in 
three categories: (i) the “HPMP” (i.e., 3-hydroxy-2-phosphonylmethoxypropyl) derivatives, 
represented by HPMPC (cidofovir, CDV), which displays activity against a broad variety of DNA 
viruses, (ii) the “PME” (i.e., 2-phosphonylmethoxyethyl) derivatives with activity against DNA viruses Viruses 2010, 2   
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and retroviruses, and iii) the “PMP” (i.e., 2-phosphonylmethoxypropyl) derivatives, represented by, 
respectively, PMEA (adefovir) and PMPA (tenofovir). These three representative compounds have 
been licensed for the treatment of HCMV retinitis in AIDS patients (CDV, Vistide
®), chronic hepatitis 
B virus infections (adefovir dipivoxil, Hepsera
®) and HIV infections (tenofovir disoproxil fumarate, 
TDF, Viread
®). TDF is also available in a fixed-dose combination form with emtricitabine (Truvada
®) 
or emtricitabine and efavirenz (Atripla
®) for the treatment of AIDS.  
More recently, two new generations of ANPs have been synthesized. The second   
generation of ANPs includes the 2,4-diaminopyrimidine (DAPy) derivatives: HPMPO-DAPy   
[(R)-6-(3-hydroxy-2-(phosphonylmethoxy)propoxy)-2,4-diaminopyrimidine], PMEO-DAPy [6-(2-
(phosphonylmethoxy)ethoxy)-2,4-diaminopyrimidine], and 5-X-substituted derivatives thereof, and 
PMPO-DAPy [(R)-6-(2-(phosphonylmethoxy)propoxy)-2,4-diaminopyrimidine] [3–5]. The third 
generation of ANPs comprises the ANPs containing as a base moiety 5-azacytosine; among them  
1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine (HPMP-5-azaC,), its cyclic form 
(cHPMP-5-azaC) and ester prodrugs. From the structural point of view, HPMP-5-azaC is a   
5-azacytosine analog of CDV, 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine [6,7].  
2. Anti-poxvirus Activity in vitro  
CDV was found to be effective against a broad range of DNA viruses, including adeno-, herpes-, 
irido-, hepadna-, papilloma-, polyoma- and poxviruses. All herpesviruses of human and veterinary 
importance are inhibited by CDV. Particularly important is the activity of CDV against: 
(i) adenoviruses for which there is currently no drug treatment; (ii) herpes simplex virus (HSV) and 
varicella-zoster virus (VZV) mutants resistant to acyclovir due to mutations in the viral thymidine 
kinase (TK); (iii) HCMV mutants with alterations in the viral UL97 gene, whose product is responsible 
for the activation of ganciclovir; (iv) Epstein-Barr virus (EBV), for which no antiviral treatment is 
available; (v) polyoma- and papillomavirus, for which also no therapy is currently approved; and (vi) 
poxviruses, including variola virus, which is considered as a possible bioterrorist weapon.  
The in vitro activity of CDV against vaccinia virus (VACV) was first mentioned in the context of a 
comparative study with HPMPA. CDV was found to inhibit VACV replication in vitro at an IC50 of 
4 µg/mL, while under the same conditions HPMPA showed an IC50 of 0.7 µg/mL against VACV [1]. 
Several studies later on confirmed the activity of CDV against VACV and enlarged the spectrum of 
activity of CDV against several orthopoxviruses [i.e., cowpox (CPXV), camelpox (CMLV), 
monkeypox (MPXV), ectromelia virus (ECTV), and variola (VARV)]. In fact, from all the poxviruses 
evaluated for their susceptibility to the inhibitory effects of CDV, variola virus proved to be one of the 
most sensitive orthopoxviruses [8–11]. Further studies have ascertained that CDV is also effective 
against parapoxviruses, a group of viruses that cause orf in sheep and goats, pseudocowpox in cattle 
and skin lesions in deer, seals, squirrels and camels [12].  
A summary of the activity spectrum against poxviruses described for the different generations of 
ANPs is given in Figure 2. Among the O-linked ANP analogues, HPMPO-DAPy was found to exhibit 
selective and potent activity against several poxviruses in vitro. Comparison of CDV and its   
5-aza analog showed that anti-poxvirus activity and selectivity data of HPMP-5-azaC are similar, or in 
some cases higher, than CDV [6,7]. It should be noticed that for a number of the ANPs, the activity Viruses 2010, 2   
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against certain poxvirus, such as ECTV, MPXV, VARV, and molluscum contagiosum virus (MCV) 
has not been evaluated yet. 
Figure 2. Spectrum of anti-poxvirus activity of CDV and other acyclic nucleoside 
phosphonates (ANP)s. The antiviral properties of ANPs others than HPMPC (CDV) 
against variola virus, monkeypox virus and molluscum contagiosum virus has not been 
determined yet. ND: not determined. 
 
Anti‐poxvirus activity of representative ANPs from different generations
VACV CPXV CMLV Orf virus
(S)‐HPMPC 2.2 5.1 4.4 0.33
(S)‐HPMPA 0.5 0.7 0.16 0.08
(S)‐HPMPDAP 0.1 0.3 0.14 0.43
(R)‐HPMPO‐DAPy 0.46 0.3 0.7 0.51
PMEO‐DAPy 28 44.6 >50 25.4
(S)‐HPMP‐5‐azaC 1.7 3.2 2.6 0.23
EC50: 50% effective concentration or concentration required to reduce virus cytopathic 
effect by 50%.
EC50 (µg/mL) Compound
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Inhibition of poxvirus replication by CDV in combination with other agents has not been much 
investigated. Vigne et al. [13] found strong synergistic effects when CDV was combined with small 
interfering RNAs (siRNAs) targeting the D5R, B1R, or G7L genes that encode for, respectively, a 
DNA-independent nucleoside triphosphatase, a serine/threonine kinase, and a protein of the core of the 
intracellular mature virus.  
At first, most of these experiments were performed in monolayer cell culture assays. More recently, 
VACV, CPXV, CMLV, and orf virus were shown to replicate efficiently in three-dimensional 
epithelial raft cultures, using human or lamb keratinocytes, giving histological pictures comparable to 
that described for the skin biopsy specimens of the corresponding diseases. In these conditions, CDV 
and several acyclic nucleoside analogs exhibited the expected selective antiviral activity [14–16]. 
3. Intracellular Metabolism  
3.1. Cellular Uptake 
The negative charge of the phosphonate moiety of the ANPs significantly impairs their cellular 
uptake. Their membrane transport is an active process and it is significantly slower and less efficient 
than that of nucleoside analogs, which can cross the cell membrane by the nucleoside transport carrier 
system or by passive diffusion. It has been suggested that the cellular uptake of ANPs occurs via an 
endocytosis-like process with slow kinetics and marked temperature dependence [17].  
In a later study, Connelly and collaborators [18] studied the uptake of CDV into Vero cells and their 
data confirmed that the uptake of CDV was temperature sensitive: the rate of uptake was considerably 
lower at 27 °C than at 37 °C and almost totally inhibited at 4 °C. The uptake of [
3H]CDV into Vero 
cells was compared to that of [
14C]sucrose, an indicator for fluid-phase endocytosis. The uptake 
kinetics for both [
3H]CDV and [
14C]sucrose into Vero cells were very similar, as well as the effects of 
the microtubule antagonist colchicine (inhibitor of endocytosis) and of the tumor promoting agent 
phorbol myristate acetate (stimulator of endocytosis). It was, thus, concluded that CDV enters the  
cells via fluid-phase endocytosis and that once internalized it may accumulate in the lysosome. 
Protonation of the negative charge on the phosphonyl group in CDV may permit its diffusion across 
the lysosome membrane and then in the cell cytoplasm the compound is converted to the active 
diphosphorylated form. 
3.2. Activation and Intracellular Half-life 
Once in the cytoplasm, CDV needs only two phosphorylation steps to be converted to its antiviral 
active diphosphoryl derivative, i.e., CDV-pp (CDVpp) (Figure 3). The two phosphorylation steps are 
carried out by cellular enzymes [19]. In this way, CDV is independent of the first phosphorylation step, 
which in the acyclic nucleoside analogs (such as acyclovir and ganciclovir) is catalyzed by the HSV or 
VZV encoded TK or the HCMV encoded protein kinase UL97. Therefore, the compound is active 
against TK deficient HSV and VZV mutants and UL97 HCMV mutants. In a study performed by 
Bronson et al. [20], the metabolism of CDV was shown to remain unchanged between uninfected and 
infected cells, indicating that neither viral enzymes nor viral-induced enzymes are required for the 
activation of the compound. Viruses 2010, 2   
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Pyrimidine nucleoside monophosphate (PNMP) kinase catalyzes the first step of phosphorylation 
(CDV → CDVpp); whereas the second step (CDVp → CDVpp) is catalyzed by nucleoside diphopsphate 
(NDP) kinase, pyruvate kinase or creatinine kinase. CDVpp can be used by the choline phosphate 
cytidyl transferase to form the CDVp-choline adduct, according to the reaction: CDVpp + choline 
phosphate → CDVp-choline + pyrophosphate [21].  
A general feature of CDV is the long intracellular half-life of the diphosphoryl metabolites, which 
allows infrequent dosing of the compounds. The long-lasting antiviral action of CDV may be attributed 
to the long half-life of the CDV metabolites (i.e., CDVp, CDVpp and CDVp-choline) that are formed 
intracellularly following uptake of CDV by the cells. After removal of CDV from the cell culture 
medium, the intracellular levels of CDVp and CDVpp show a biphasic decline with half-lives of ~24 h 
and ~65 h [21,22]. This is most probably due to the accumulation of the CDVp-choline metabolite, 
which has a half-life of ~87 h, and may be considered to be a reservoir or depot form for CDV [21]. 
4. Mechanism of Antiviral Activity 
The antiviral effect of CDV is the result of a selective interaction of its diphosphoryl metabolite 
with the viral DNA polymerases; the specificity of CDV derives in part from a higher affinity of 
CDVpp for viral DNA polymerases than for host-cell polymerases. The binding affinity of CDVpp for 
HCMV DNA polymerase, as represented by the inhibition constant (Ki), is of 6.6 µM, which is 
approximately 8- to 80-times greater than for human DNA polymerases [Ki = 51 µM (DNA 
polymerase α), Ki = 520 µM (DNA polymerase β) and Ki = 299 µM (DNA polymerase γ)] [23–25]. 
The inhibition constants for CDVpp for other herpes viral DNA polymerases have also been 
determined; the Ki values against HSV-1 and HSV-2 polymerases are, respectively, 0.86 µM and 
1.4 µM, providing a selective binding affinity of up to 600-fold for the viral enzymes [24]. 
How does CDVpp interfere with viral DNA synthesis? CDVpp can serve as a competitive inhibitor 
with respect to the natural substrate, i.e., dCTP, or it can act as an alternative substrate and then be 
incorporated after removal of the pyrophosphate group [25]. Since CDV contains a hydroxyl function 
in the acyclic side chain, its incorporation does not inevitably result in chain termination.  
The principles of the mode of antiviral action of CDV have been first studied for CMV. Xiong and 
colleagues [23,26] have indicated that HCMV DNA polymerase incorporates CDV into the DNA with 
correct fidelity and the fidelity of DNA elongation is maintained following the incorporated CDV. It is 
incorporated internally into DNA by HCMV DNA polymerase. Incorporation of a single molecule of 
CDV slows down HCMV DNA synthesis by 31%; incorporation of two molecules of CDV separated 
by one or two natural nucleotides drastically slows down DNA synthesis, whereas incorporation of two 
consecutive molecules of CDV completely prevents DNA elongation by HCMV DNA polymerase. 
HCMV DNA polymerase associated 3' → 5' exonuclease activity cannot excise CDV from the 3' end 
due to the presence of the phosphonate group in the incorporated CDV molecule; and the rate of DNA 
synthesis slows down by 90% when using a DNA template that contains one internally incorporated 
CDV molecule. Thus, CDV can interfere with HCMV DNA synthesis in a number of ways, the most 
efficient being DNA chain termination following two consecutive incorporations of CDV at the   
3'-end. The inhibition of HCMV DNA polymerase by CDVpp and the inability of HCMV DNA Viruses 2010, 2   
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polymerase to excise incorporated CDV from DNA may account for the potent and long-lasting   
anti-HCMV activity of CDV [26]. 
Figure 3. Mechanism of action of Cidofovir (CDV). Once inside the cells, CDV needs to 
be activated by cellular enzymes. Pyrimidine nucleoside monophosphate (PNMP) kinase 
catalyses the conversion of CDV (CDV) to CDV-monophosphoryl (CDVp), which is then 
further phosphorylated to the active form, CDV-diphosphoryl (CDVpp) by nucleoside   
5'-diphosphate (NDP) kinase. CDVp-choline is considered to serve as an intracellular 
reservoir for the mono- and diphosphoryl derivatives of CDV. The diphosphoryl derivative 
of CDV (i.e., CDVpp) interacts with the viral DNA polymerase as either competitive 
inhibitors [with respect to the natural substrates (i.e., dCTP)] or alternative substrates (thus 
leading to incorporation into DNA). CDV has a hydroxyl function in the acyclic side chain 
that would allow further chain elongation. For human cytomegalovirus (HCMV), chain 
termination occurs when two consecutive CDVpp are incorporated in the growing   
DNA chain. The mechanism of action of CDV and (S)-HPMPA against VACV DNA 
polymerase compared to CMV polymerase was adapted from [27]. 
 
 
 
 
The mechanism of inhibition of the E9L DNA polymerase of VACV is somewhat different from 
that of HCMV. Recently, Magee and collaborators have studied the effect of CDVpp and HPMPApp 
on VACV DNA polymerase [28,29]. CDVpp is a poor substrate for DNA synthesis relative to dCTP. 
CDVpp can be faithfully incorporated into primer strands by VACV DNA polymerase without a 
complete inhibition of further chain elongation. However, incorporation of consecutive CDVpp 
Virus DNA 
polymerase
Active metabolite Action / result
Blocking of 
template strand 
extension
Inhibition of 3’‐to‐5’ 
exonuclease
proofreading activity
CMV (UL54) CDVpp Incorporation of 1 CDVpp  + any dNTP→ slows 
chain extension
Incorporation of 2 consecutive CDVpp → chain 
termination
Not determined +
VACV (E9L)
CDVpp Incorporation of CDVpp + any dNTP → primer 
extension significantly reduced
++
(S)‐HPMPApp Incorporation of one or more (S)‐HPMPApp → 
no effect on primer extension
++Viruses 2010, 2   
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residues into the primer strand does impede elongation rates. The authors also showed that both 
CDVpp can be excised from the primer 3' terminus by the 3'-to-5' proofreading exonuclease activity of 
VACV polymerase, but DNAs bearing CDVpp as the penultimate 3' residue are refractory to removal 
by VACV DNA polymerase’s 3'-to-5' proofreading activity. More recently, an additional mechanism 
of action of CDV was discovered. Magee et al. showed that templates containing a CDV residue 
cannot be extended beyond the CDV base by the VACV DNA polymerase [29]; CDV creates a lesion 
that further blocks elongation by the VACV DNA polymerase and, thus, effectively blocks further 
rounds of replication. 
When the mechanism of action of HPMPA diphosphate on the vaccinia E9L DNA polymerase was 
studied, some differences with CDVpp were seen [29]. Surprisingly, unlike CDVpp, (S)-HPMPApp is 
an excellent substrate for the E9L polymerase (Km and Vmax similar to that of dATP). (S)-HPMPApp is 
readily incorporated into the growing DNA strand and, unlike CDVpp, it does not slow chain 
extension but blocks 3'-to-5' exonuclease activity when in the penultimate position (Figure 3). At the 
primer terminus, (S)-HPMPApp can still be excised. Similarly to CDVpp, when (S)-HPMPApp is 
incorporated into the template strand, it strongly inhibits trans-lesion DNA synthesis. If nucleotide 
analogues are incorporated into the template strand, they can severely inhibit polymerase activity, 
similarly to some forms of DNA damage. This mode of action is not relevant for most DNA 
polymerase inhibitors because the majority of them are obligate chain terminators. In the case of   
(S)-HPMPA, (S)-HPMPApp is a good substrate but not an effective chain terminator and it may act 
more by inhibiting secondary rounds of DNA synthesis. The relatively greater efficacy of (S)-HPMPA 
in comparison to CDV can be explained by a combination of factors related to higher intracellular 
levels of (S)-HPMPApp plus a superior likelihood that (S)-HPMPA would be incorporated into an 
irreparable DNA lesion. Since (S)-HPMPApp is readily incorporated into DNA and does not slow 
chain extension, many (S)-HPMPApp residues may be incorporated into the template strand and 
templates containing (S)-HPMPA cannot be extended, blocking further rounds of replication and 
leading to template strand inhibition [29]. 
Since CDV and (S)-HPMPA inhibited VACV DNA polymerase more severely when incorporated 
into the template strand, mostly affecting secondary rounds of DNA synthesis; they are expected to 
compromise different processes, including virus assembly. Jesus and collaborators have analyzed the 
effects of CDV on the replicative cycles of distinct VACV strains [30]. They showed that despite an 
approximately 90% inhibition of production of virus progeny, virus DNA accumulation was reduced 
only 30%, and late gene expression and genome resolution were unaltered. Electron microscopic 
analysis of virus-infected cells treated with CDV revealed a reduction in the number of mature forms 
of virus particles, along with an increase in the number of spherical immature particles. They detected 
inhibition of genome encapsidation and proteolytic processing of the precursors p4a and p4b, 
ultimately leading to the impairment of virus morphogenesis. However, these effects of CDV on virus 
morphogenesis resulted from a primary effect on virus DNA synthesis, which led to later defects in 
genome encapsidation and virus assembly. Analysis of virus DNA by atomic force microscopy 
revealed that viral cytoplasmic DNA synthesized in the presence of CDV had an altered structure, 
forming aggregates with increased strand overlapping not observed in the absence of the drug. These 
aberrant DNA aggregations were not encapsidated into virus particles. The authors hypothesized that 
the incorporation of CDV into DNA molecules by the viral DNA polymerase would be the first step Viruses 2010, 2   
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towards the downstream effect of the drug on virus morphogenensis, possibly related to alterations of 
DNA structure and subsequent impairment of DNA encapsidation. Alterations in DNA structure 
induced by the incorporation of nucleoside analogues could compromise the interaction of DNA with 
DNA-binding proteins and the subsequent encapsidation of the viral genome. 
Watanabe and Tamaki [31] have shown that CDVpp (at concentrations of 20-50 µM) was able to 
inhibit MCV DNA polymerase activity, providing support for CDV as a treatment for severe cases of 
molluscum contagiosum.  
5. Mechanism of Resistance 
So far, there is no conclusive evidence of selection of cytomegalovirus (or other viruses) resistant to 
CDV in patients receiving treatment with CDV. Clinical failure of CDV has not been related to the 
emergence of drug-resistant strains so far. Characterization of in vitro selected CDV resistant 
herpesviruses has clearly shown that CDV resistant is linked to mutations in the viral   
DNA polymerase. 
Similarly to herpesviruses, exposure of poxviruses to increasing concentrations of CDV in vitro 
selects for drug-resistant viruses with mutations in the E9L gene (DNA polymerase) [32]. These 
mutations are located at the 3'-to-5' exonuclease domain and the 5'-to-3' polymerase domain of the 
VACV DNA polymerase. Independent studies found that VACV strains that have been passaged under 
increasing concentrations of CDV bear either an alanine-to-threonine or an alanine-to-valine change at  
position 314 in the viral DNA polymerase [33–35]. By marker transfer experiments it could be 
demonstrated that the A314T substitution could confer a 5-fold increase in CDV resistance in VACV 
compared to the wild-type virus [33]. Considering this residue’s location in the putative exonuclease 
domain of the viral polymerase, this substitution may alter the ability of the enzyme to remove CDV 
residues from the viral polymerase. The alanine-to-valine substitution at position 684 in the putative 
polymerase domain was also shown by marker rescue experiments to confer resistance to CDV 
independently of the A314T substitution, although the degree of resistance was significantly lower 
than the virus encoding both mutations [33]. Interestingly, the A314T recombinant virus and the 
A684V recombinant viruses showed differences in sensitivity to the pyrophosphate analogue   
PAA: the A314T mutation conferred hypersensitivity to PAA; the A684V substitution showed 
increased resistance to PAA, while the presence of both mutations resulted in no change in   
susceptibility to PAA [33].  
Several other substitutions in the exonuclease domain and the polymerase domain in the VACV 
DNA polymerase of CDV-resistant viruses have been reported [34,35]. A summary of the different 
mutations identified in viruses isolated under selective pressure with CDV is presented in Figure 4. 
Becker et al. reported [34] that the A314V substitution is able to confer a seven-fold resistance to CDV 
and these viruses were shown to grow poorly in cell culture. In contrast, the virus bearing the A314T 
amino acid change proved to replicate as well as the wild-type in cell-culture. Thus, even if the level of 
resistance conferred by the two substitutions appeared to be equivalent, the viruses encoding the 
A314T substitution appeared to be more fit in cell culture than viruses encoding the A314V change. 
Consistent findings were found when the pathogenicity of the A314T and A314V mutants were 
evaluated in mice since both mutant viruses displayed impaired pathogenicity compared to the   Viruses 2010, 2   
 
 
2812
wild-type virus. Also the A684V and the double mutant A314 + A684V viruses exhibited reduced 
virulence in mice, demonstrating that these DNA polymerase mutations are linked to reduced fitness  
in vivo [33–35]. Interestingly, it was shown that infections caused by CDV
r VACV were still treatable 
with CDV treatment. It was observed that treatment for five days with CDV at 10 or 50 mg/kg once a  
day still protected mice against an intranasal challenge with the drug-resistant virus bearing both 
mutations [33]. 
Figure 4. Location of mutations in CDV-resistant E9L (DNA polymerase) mutants. 
 
 
In a recent study, it was demonstrated that the 3'-to-5' proofreading exonuclease activity of VACV 
DNA polymerase is essential, and plays a key role in promoting genetic recombination [36]. In 
addition, a VACV DNA polymerase bearing the A314T substitution can overcome the inhibitory 
effects of CDV in both in vitro recombination and exonuclease assays. Thus, the A314T substitution 
enhanced the enzyme’s capacity to excise CDV molecules from the 3' ends of duplex DNA and to 
recombine these DNAs in vitro, when experiments were performed using purified mutant DNA 
polymerase. Importantly, CDV was able to block the formation of concatemeric recombinant molecules 
in vitro in a process that was catalyzed by the proofreading activity of VACV DNA polymerase. 
Recombination was also inhibited when CDV-containing recombination substrates were transfected into 
cells infected with wild-type virus but not if transfected into cells infected with the virus bearing the 
A314T mutation mapping within the 3'-5' exonuclease domain of the viral DNA polymerase. 
Kornbluth and colleagues described a CDV
r VACV, which was found to encode five amino acid 
changes: four in the exonuclease domain (H296Y, A314V, H319W, S338F) of the VACV E9L 
polymerase and one in the polymerase domain (R604S) [35]. Transfer of this mutant E9L gene into 
wild-type VACV by marker rescue conferred the drug-resistance phenotype. However, the role of 
these mutations has not been clearly established because viruses encoding individual mutations were Viruses 2010, 2   
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not isolated. E9L polymerase mutations occurred sequentially during passage in CDV, and an 
H296Y/S338F double mutant that conferred an intermediate CDV resistance phenotype was identified. 
In vitro, the marker-rescued CDV-resistant VACV containing all five mutations grew nearly as well as 
wild-type VACV. However, the virulence of this virus for mice was reduced, as 10- to 30-fold more 
CDV-resistant virus than wild-type virus was required for lethality following intranasal challenge. A 
single dose of CDV 50 or 100 mg/kg gave 60 to 80% survival versus 20% in untreated animals.  
Thus, independent investigations have shown that CDV
r VACV are less virulent in mice and despite a 
9- to 14-fold in vitro resistance, the disease can be treated effectively with CDV. 
In a recent study, a comparative whole genome sequence analysis of wild-type and CDV
r MPXV 
revealed 55 single-nucleotide polymorphisms (SNPs) and one tandem-repeat contraction [37]. Over 
one-third of all identified SNPs were located within genes comprising the poxvirus replication 
complex, including the DNA polymerase, RNA polymerase, mRNA capping methyltransferase, DNA 
processivity factor, and poly-A polymerase. Four mutations were found in the DNA polymerase gene, 
including the A314V and A684V mutations. The significance of the two other mutations in the viral 
DNA polymerase (A613T and T808M) on CDV resistance is not known. Also, both the A314V and 
A684V mutations have been reported in a cowpox CDV
r strain [38]. These data suggest that the 
mechanism of CDV resistance may be highly conserved across orthopoxviruses.  
It should be noted that in the process of selection of CDV
r mutants, the A684V mutation appeared 
to be selected after the A314T mutation and that the A314T/V mutation has also been reported in 
viruses selected for resistance to other ANPs [33]. In fact, the A684V substitution has not been 
reported to occur alone following selection with either CDV or other ANPs; it has systematically been 
found in combination with other changes in the DNA polymerase of orthopoxviruses. The A684V 
mutation in combination with the S851Y substitution has been found in a VACV strain selected under 
pressure with (S)-HPMPDAP [39]. A recombinant virus bearing only the S851Y mutation exhibited a 
low level of resistance to dCMP analogues but high-level resistance to dAMP analogues and   
to 6-[3-hydroxy-2-(phosphonomethoxy)propoxy]-2,4-diaminopyrimidine, which is considered to 
mimic the purine ring system. The S851Y virus showed a reduced fitness in vitro and in vivo.  
6. In Vivo Efficacy in Animal Models for Poxvirus Infections 
Several animal models using mice (most frequently), rabbits, or monkeys have been used to 
demonstrate the activity of CDV against orthopoxvirus infections (reviewed in [40,41]). The treatment 
of VACV infections have been well studied in models involving infection of scarified skin, or resulting 
from intravenous, intraperitoneal, intracerebral, or intranasal virus inoculation. CPXV has been used in 
intranasal or aerosol infection studies to evaluate the treatment with CDV of lethal respiratory 
infections. Monkeypox, ectromelia, and variola viruses have been employed to a lesser extent than the 
other viruses. Also, the efficacy of topical CDV against orf virus in lambs has been described [42]. A 
summary of the efficacy of CDV in different models of poxvirus infections in presented in Table 1. 
An interesting study has compared the effectiveness of post-exposure smallpox vaccination and 
antiviral treatment with CDV or with the related analogue HPMPO-DAPy after intratracheal infection 
of cynomolgus monkeys with MPXV [43]. Beginning antiviral treatment 24 h after lethal intratracheal 
MPXV infection with either drug following various treatment regimens resulted in a significant Viruses 2010, 2   
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reduction in the number of cutaneous MPXV lesions and in mortality. In contrast, vaccination of 
monkeys 24 h after MPXV infection did not result in reduction of mortality, indicating that antiviral 
treatment with CDV is more effective than smallpox vaccination upon lethal MPXV infection. 
Another study has evaluated the effects of coadministration of CDV and smallpox vaccine in 
monkeys [44]. The data indicated that a single-dose vaccination regimen including the smallpox 
vaccine Dryvax and CDV reduced VACV loads after vaccination and Dryvax-mediated   
vaccination complications. However, coadministration of CDV + Dryvax also significantly decreased  
Dryvax-elicited antibody and T-cell responses and impaired Dryvax-induced immunity against MPXV. 
7. Dosage and Administration 
CDV has been approved and marketed worldwide (Vistide
) for the treatment of HCMV retinitis in 
AIDS patients. The compound has to be given intravenously at a dose of 5 mg/kg once weekly for two 
weeks followed by 5 mg/kg intravenously once every other week. Strict monitoring of renal function 
before initiation of CDV therapy and concomitant administration of oral probenecid and intravenous 
hydration are required to minimize drug-related nephrotoxicity. The compound has been used   
off-label topically as a 3% or 1% cream formulated in different bases. No oral formulations are 
currently available. 
Since the use of CDV is limited by its poor oral bioavailability and renal toxicity, Hostetler’s group 
has synthesized alkoxyalkyl esters of CDV and its cyclic form, i.e., c-CDV [45-47]. Esterification of 
cidofovir with an alkoxyalkyl group facilitated drug adsorption in the gastrointestinal tract. These 
alkoxyalkyl esters of CDV and its cyclic form were much more active in vitro than the parent 
compounds against several herpesviruses, and poxviruses. The increased activity of alkoxyalkyl esters 
of CDV compared to the parent compound CDV was also shown against adenovirus, polyomavirus, 
and papillomavirus [48–50]. In addition, these derivatives showed improved uptake and absorption, 
and had oral bioavailabilities in mice of 88–97%, compared to less than 5% for CDV. Studies with 
radiolabeled compound confirmed increased cell penetration (10–20 fold) and higher intracellular 
levels (100-fold) of diphosphorylated CDV (the active form of the compound) than those measured 
following treatment of the cells with CDV [51]. In vivo, oral administration of the hexadecyloxypropyl-
CDV (HDP-CDV) proved as effective as parental CDV in the treatment of herpes- and poxvirus 
infection in several mouse models [52–54]. Importantly, diminished accumulation of the drug in the 
kidney was reported according to studies evaluating tissue distribution of radiolabel HDP-CDV and 
other alkoxyalkyl esters of CDV in mice [55,56]. If no accumulation of these prodrugs is also observed 
in the clinic, these compounds may avoid the dose-limiting toxicity of CDV. 
HDP-CDV (CMX001) in an oral formulation is presently under development by Chimerix. A Phase 
I clinical study to evaluate the safety and pharmacokinetics of orally administered CMX001 in healthy 
volunteers is completed and Phase II trials are ongoing in CMV infections in stem cell transplant 
recipients and polyoma BK virus infection in kidney transplant patients. CMX001 is also under 
consideration to be included in the Strategic U.S. Stockpile for emergency use in case of a bioterrorist 
attack with VARV or for treatment of smallpox vaccination in case massive vaccination should   
be required. 
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8. Pharmacology 
The pharmacokinetic properties of CDV in humans have been reported for the intravenous 
preparation; CDV exhibited dose-independent pharmacokinetic features [57]. The clinical 
pharmacokinetic properties of CDV following single intravenous infusion at the recommended dosage 
regimen (5 mg/kg, with concomitant oral administration of probenecid) have been reviewed based on 
data compiled from three Phase I/II studies in HIV infected patients without CMV infection or with 
asymptomatic retinitis: Cmax (peak serum concentration) of 19.6 ± 7.18 mg/L; AUC0 → ∞ (area under 
the serum concentration-time curve from zero to infinity) of 40.8 ± 8.97 mg/L h; creatinine clearance 
(based on serum creatinine concentration) of 0.138 ± 0.036 L/h/kg; renal clearance of 0.096 ± 0.031 
L/h/kg; steady state volume of distribution of 0.39 ± 0.13 L/kg; and a plasma elimination half-life 
(t1/2β) of 2.2 ± 0.5 h) [58].  
It should be noted that conventional pharmacokinetic measurements do not accurately reflect the 
duration of action of CDV, since the antiviral effect is dependent on the intracellular concentrations of 
the active phosphorylated metabolites within cells [59]. As mentioned above, the metabolites of CDV 
have a long intracellular half-life (48 h for the CDVp-choline adduct), which may contribute to the 
prolonged antiviral action of CDV.  
Brody and colleagues reported on the pharmacokinetic properties of CDV in patients with renal 
insufficiency [60]. A significant correlation was observed between creatinine clearance and CDV 
clearance in patients with varying degrees of renal insufficiency; indicating the necessity to adjust the 
CDV dose in patients with kidney disease to ensure comparable drug exposure based on serum levels. 
Although CDV is contraindicated in subjects with renal impairment function, in this study, the authors 
provide theoretical dosing guidelines for this population of patients with reduced doses of CDV that 
would produce the required systemic exposure to CDV. 
A limited amount of data is available concerning the systemic distribution of CDV following 
intralesional or topical application. CDV serum dosages were reported in a study performed to evaluate 
the efficacy of intralesional injections of CDV in patients suffering from severe laryngeal 
papillomatosis [61]. The patients received different numbers of CDV injections, and a total of 121 
CDV injections were undertaken in a total of 17 patients (drug concentration = 2.5 mg/mL). Five series 
of CDV serum dosages were performed in three different patients. The drug could be detected in two 
patients: in one case the concentration of CDV in serum was 0.36 µg/mL 10 min after injection; in the 
second case the serum dosages were done on three different occasions and the drug could be detected  
at 5, 10, and 15 min after the end of injection; the concentrations of CDV were 0.59, 0.60,   
and 0.42 µg/mL, respectively. For the third patient and the two other series of serum dosages, the 
passage of CDV in the bloodstream, from the intralesional injections, could not be demonstrated.  
In a later study, a linear relationship between CDV plasma concentration and dose in children, but 
not in adults, was found following local CDV injections in respiratory papillomatosis [62]. The same 
relationships were found between dose and area under the concentration/time curve (AUC). From this 
study, it was concluded that the CDV plasma levels were below those leading to toxicity and the levels 
and the AUC were dose dependent in children but not in adults. Diffusion from the injected site was 
the greatest and unpredictable among adults. Due to the great individual variation in diffusion in Viruses 2010, 2   
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adults, it is recommended to use CDV at a lower dose than the recommended intravenous dose to 
prevent any risk of systemic toxicity [63].  
No studies have been performed on CDV distribution following topical administration of the drug. 
The bioavailability and metabolism of CDV was studied in New Zealand white rabbits following 
topical administration to normal and abraded skin [64]. Concentrations in kidney following topical 
administration of CDV to normal skin were <4% of those following intravenous dosing. Topical 
application of CDV to intact skin led to negligible systemic exposure to the drug. However, the topical 
bioavailability and hence the flux of CDV through intact skin, was enhanced in abraded skin. Thus, 
abrasion of the skin removed the principal barrier to absorption and led to significant systemic 
exposure to CDV; therefore, it is recommended to take systemic exposure following application of the 
drug to abraded skin into account. 
9. Safety 
Most toxicity issues associated with CDV are related to intravenous use of the drug. CDV has been 
associated with nephrotoxic side-effects in various species, i.e., mice, rats, guinea pigs, rabbits   
and monkeys. Guinea pigs appeared to be particularly susceptible to the nephrotoxic effects of   
CDV [65,66]. Nephrotoxic side effects of CDV were also observed during the initial clinical studies 
with CDV in HCMV-infected patients. Nephrotoxicity associated with CDV manifested by 
proteinuria, glycosuria, and decreases in serum phosphate, uric acid, and bicarbonate, increases in 
serum creatinine, and degeneration and necrosis of the proximal renal tubule cells [67–69]. 
The nephrotoxicity associated with CDV is explained by the fact that the active uptake of the 
compound at the basolateral membrane of the kidney proximal tubular cells is faster than the efflux of 
CDV at the luminal-side (i.e., into the urine), thus resulting in the accumulation of CDV or its 
metabolites in the renal tubular cells [70]. The human organic anion transporter 1 (hOAT1) was shown 
to interact with CDV as well as other acyclic nucleoside phosphonates. hOAT1 proved to play a 
critical role in the organ-specific toxicity of CDV [70–72] Recently, a study was conducted to 
investigate whether the other renal organic anion transporter hOAT3 and organic cation transporter 
hOCT2 transport these antivirals. The hOCT2 did not increase uptake of the antivirals; furthermore 
CDV (as well as adefovir and tenofovir) are substrates of hOAT3 as well as hOAT1, but quantitatively 
hOAT1 appeared to be the major renal transporter for acyclic nucleoside phosphonates [73]. 
In addition to intravenous hydration, the accumulation of CDV in the renal tubular cells can be 
prevented by an infrequent treatment schedule and the co-administration of probenecid, an inhibitor of 
organic anion transport that interferes with the transporter-mediated tubular uptake of CDV [74]. Oral 
probenecid coadministration has been shown to effectively protect monkeys receiving chronic 
intravenous CDV. In addition, to avoid nephrotoxicity, CDV should not be dosed higher than 5 mg/kg 
(intravenously) once weekly for two weeks, followed by 5 mg/kg every other week. The infrequent 
dosing of CDV, which still affords a significant antiviral activity, is based on the long lasting activity 
of the diphosphorylated metabolite of CDV.  
No systemic side effects have been reported upon topical or intralesional CDV administration, 
although local reactions (i.e., inflammatory response) may occur at the application site [75,76]. In a 
phase II double-blind placebo-controlled study, CDV 1% topical gel was shown to be effective in the Viruses 2010, 2   
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treatment of anogenital warts, the side effects in the CDV- and placebo-treated groups being 
comparable [77]. 
Inflammation and/or erosion may occur at the site of application of CDV cream in patients [78]. 
Such erosions invariably heal and may actually reflect an effective response of the viral lesions to CDV 
treatment, although care should be taken not to apply CDV on abraded skin. Also, topical application 
should not exceed a concentration of 1%. If applied at a too high concentration over a too large surface 
of abraded skin, there is a risk of systemic toxicity, as illustrated by a case of acute renal failure in a 
bone marrow transplant recipient who was treated with topical CDV 4% for 12 consecutive days [79]. 
10. Clinical Efficacy of CDV in the Treatment of Poxvirus Infections 
CDV is licensed for the treatment of CMV retinitis in AIDS patients; however, it has been used  
off-label for the treatment of infections caused by other herpesviruses and several DNA viruses,   
i.e., polyoma-, papilloma-, adeno-, and poxviruses. CDV has great potential for the therapy and 
prophylaxis of poxvirus infections, including orthopox (smallpox, monkeypox, cowpox and vaccinia), 
parapox (orf) or molluscipox (molluscum contagiosum). Also, CDV appears particularly indicated for 
the treatment of complications arising from vaccination with the life vaccinia vaccine in 
immunocompromised patients (i.e., progressive disseminated vaccinia, vaccinia gangrenosa, etc.) and 
other patients (i.e., accidental vaccinia, eczema vaccinatum, etc.) in case smallpox vaccination should 
become necessary again [80,81]. Vaccination of immunosuppressed patients would be absolutely 
contraindicated, but inadvertent use of the life vaccine in this group of patients may lead to a serious, 
life-threatening disseminated and progressive vaccinia. Based on the data obtained in experimental 
animal models, CDV may be expected to be effective in the therapy as well as the pre- and   
post-exposure prophylaxis of smallpox, monkeypox and vaccinia virus infections in humans. Recently, 
a dramatic case of eczema vaccinatum in a child following infection from his father who has been 
vaccinated for smallpox was reported. The child was successfully treated with Vaccinia Immuno 
Globulin (VIG) and two antiviral agents, i.e., CDV and ST-246, an anti-poxvirus drug that inhibits the 
morphogenesis of orthopoxviruses [82]. CDV was administered on the basis of standard induction 
dosing for patients with AIDS who have CMV retinitis; and only one dose was given because of 
clinical improvement over the next week. Due to the close timing of administration of each agent, it is 
difficult to precisely determine the contribution of each agent to the patient’s recovery. The levels of 
VACV DNA in the blood started to decrease following VIGIV and CDV treatment, and then continued 
to decrease following ST-246 administration [83].  
Monkeypox has been considered as an emerging zoonosis after the virus was introduced into the U.S., 
and infected prairie dogs had contaminated clusters of patients in the Midwest [84–86]. While there is no 
clear clinical data on the usefulness of CDV in such patients, CDV can be used in case of emergence of a 
monkeypox outbreak since CDV was found to decrease morbidity and mortality associated with 
monkeypox infections in two animal models (Table 1). Primates treated with a single dose of CDV on 
the day of infection were completely protected from clinical and laboratory signs of disease. 
Recently, several outbreaks of cowpox in domestic animals and humans have been reported in 
Europe [87–92]. Cowpox infections in humans can lead to massive local destruction. This can lead to 
mutilation and, depending on anatomic site, significant functional disability and also aesthetic Viruses 2010, 2   
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disfigurement. Considering the efficacy of CDV in different animal models of CPXV infection, CDV 
is a promising therapeutic option for the treatment of emerging CPXV zoonosis in humans.  
CDV has been used in the clinic to treat patients with recalcitrant molluscum contagiosum. 
Meadows et al. reported three HIV seropositive patients with extensive molluscum contagiosum, two 
of whom received intravenous CDV and one of whom received topical CDV [93]. The two patients 
receiving intravenous CDV received the drug for the treatment of CMV retinitis and over one or two 
months therapy a complete resolution of the molluscum contagiosum lesions were noted. The lesions 
completely regressed in the patient receiving CDV 3% (once a day, Monday through Friday for two 
weeks) after one month therapy. Moderate inflammation appeared during the second week of therapy, 
but one month following therapy, neither molluscum contagiosum lesions nor residual inflammation 
were noted. A complete and durable resolution of molluscum contagiosum lesions was observed in 
children presenting extensive lesions following topical application of CDV 1% or 3% cream, e.g., in a 
boy with Wiskott-Aldrich syndrome [94], in two otherwise healthy children [95] and in two   
HIV-seropositive children [96]. Topical CDV (3% cream) in combination with cryotherapy has proved 
to be efficacious in the treatment of a giant facial molluscum contagiosum in an HIV   
patient [97]. After three months of treatment, more than 70% improvement in the clinical picture was 
observed, with a marked improvement after 12 months of combination therapy. Two years after 
discontinuation of all topical treatment and despite no improvement in immune status, the patient 
remained free of mollusci. 
The first report on the efficacy of CDV in the treatment of a giant orf (ecthyma contagiosum) lesion 
in an immunosuppressed patient was described in 2001 [98]. Topical treatment with 1% CDV cream 
(five cycles of 5 days with and 5 days without treatment) resulted in complete resolution of the lesion, 
with only granulation left. After some signs of recurrence, the lesion was treated with another two 
courses of CDV cream, affording a complete cure. However, in a recent case-report of a 73-old woman 
with non-Hodgkins lymphoma who developed progressive orf virus lesions, CDV administered 
topically and intralesional did not result in resolution of the lesions [99]. The patient’s orf virus 
infection regressed with topical imiquimod despite progression of her malignancy.  
11. Conclusions 
CDV remains a reference compound against poxviruses and holds potential for the therapy and 
short-term prophylaxis of poxvirus infections. Unlike ST-246, an inhibitor of orthopoxvirus 
morphogenesis, CDV can be used not only for the treatment of orthopoxviruses (smallpox, 
monkeypox, cowpox, vaccinia), but also of parapox (orf) and mollusci (molluscum contagiosum) 
viruses. Treatment of poxviruses infections should be considered not only in the case of an eventual 
bioterrorist attack with smallpox, but also poxviruses zoonosis (i.e., cowpox, monkeypox, and orf), 
considering the increasing numbers of reports of outbreaks. Also, the veterinary use of CDV should 
not be neglected. Furthermore, the management of molluscum contagiosum infections in children and 
in immunocompromised patients can be difficult and may require the use of effective antiviral agents. 
Also, the potential of novel derivatives of CDV (such as HPMP-5-azaC) as antipoxvirus agents, as 
well as CDV prodrugs (such as CMX001) for systemic treatment of poxviruses infections should  
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Table 1. Efficacy of CDV in different models of poxvirus infections. 
Animal model  Route of CDV 
administration  Evidence for Efficacy  Reference 
Intranasal or aerosolized 
CPXV infection in mice 
Subcutaneous 
One inoculation of 100 mg/kg CDV on day 0, 2, or 4 resulted in 90–100% survival. Treatment on day 0 reduced 
peak pulmonary virus titers 10- to 100-fold, reduced the severity of viral pneumonitis, and prevented pulmonary 
hemorrhage. The same dose on day -6 to 2 protected 80%–100% of infected mice, whereas one inoculation on day -
16 to -8 or day 3 to 6 was partially protective. 
[100] 
A single dose of CDV 100 mg/kg administered on the day of infection was 80 to 100% protective when given on 
day 0, 1, 2, 3, or 4 after infection. Lung virus titers (determined on day 4 of the infection) were significantly reduced 
in groups treated on day 0, 1, or 2. 
[101] 
Intranasal 
Single treatment of 20 and 40 mg/kg CDV given up to three days after virus inoculation resulted in 80–90% 
protection. A single 40 mg/kg treatment of infected mice given 1 or 2 days after infection significantly decreased 
virus titer in lungs and nose/sinus compared to the placebo group. 
[102] 
Single treatment of 5–40 mg/kg 24 h after virus exposure afforded 80–100% protection from lethal infection and 
significant reduction in viral titers in the lung tissue.  [103] 
Aerosol 
Single treatment of 1-5mg/kg CDV at 1 day before or 2 h after infection showed efficacy as measured by changes in 
body and lung weight, lung viral titers, pulmonary pathology and survival.  [104] 
Treatment with CDV was successful in protecting against lethal intranasal cowpox infection. A dose of drug in the 
range of 0.5–5 mg/kg was protective when given before (day -1), the day of infection (day 0) or after infection (day 
+1 or +2); an 80% survival rate was observed when mice were treated 2 days before challenge. 
[105] 
Intraperitoneal 
Treatment for five consecutive days starting 24 h after infection with CDV at 30 mg/kg per dose was 100% effective 
in preventing mortality.  [106] 
Treatment with CDV at 160, 80 or 40mg/kg as a single dose 24 h after virus exposure afforded 100% protection 
from lethal infection and significant reduction in viral titers in the lung tissue.  [103] 
Treatment with CDV at 6.7 mg/kg once daily for five days beginning 24 or 48 h after viral inoculation, afforded 
100% protection from lethal infection. Even when treatment was started 72 h post-infection, CDV treatment resulted 
in 66% protection. 
[107] 
CDV at a dose of 5 or 10 mg/kg administered daily beginning on day -5, -3, or -1 through day 0 (the viral 
inoculation day) afforded 93% protection from lethal infection. A single dose of 30 mg/kg CDV -1 before viral 
inoculation or 1 day post-infection resulted in 100% protection. 
[107] 
CDV at 100 mg/kg once a day on days 1 and 2 after infection resulted in 100 protection from lethal infection and 
significant reduction in viral titers in the lungs.  [108] 
CDV (100 mg/kg/day for two days starting 24 h after virus exposure) led to survival and suppression of tissue virus 
titers in animals suffering from either a lethal upper respiratory tract infection or both upper and lower respiratory 
tract infection. 
[109] 
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Table 1. Cont. 
Animal model  Route of CDV 
administration  Evidence for Efficacy  Reference 
Intranasal or aerosolized 
VACV infection in mice 
Intraperitoneal 
Treatment with CDV at 160, 80 or 40mg/kg as a single dose 24 h after virus exposure afforded 70% protection from 
lethal infection. 
[103] 
Treatment with CDV at 5 mg/kg once daily for five days beginning 24, 48, or 72 h after viral inoculation, afforded 
73–100% protection from lethal infection. 
[107] 
CDV treatment (100 mg/kg/day i.p. for two days) significantly reduced mortality and viral titers in lungs.  [108] 
Intranasal  Single treatment of 5–40 mg/kg 24 h after virus exposure afforded 70–80% protection from lethal infection and 
significant reduction in viral titers in lung tissue.  [103] 
Intraperitoneal CPXV 
infection in mice  Intraperitoneal 
CDV at 100 mg/kg once a day on days 1 and 2 after infection resulted in significant protection from lethal infection 
and significant reduction in viral titers in the lungs.  [108] 
CDV at 25 or 100 mg/kg once one day before infection resulted in significant reduction of virus replication in 
several organs.  [110] 
Intraperitoneal VACV 
infection in mice  Intraperitoneal  CDV treatment (100 mg/kg/day i.p. for two days) afforded 60% protection from lethal disease and significant 
reduction in viral titers.  [108] 
Intravenous, intranasal, 
or intraperitoneal VACV 
infection in SCID mice 
Subcutaneous  Following administration of CDV, at doses ranging from 1mg/kg/day for five days to 20 mg/kg/twice a week, death 
could be significantly delayed.  [111] 
Intranasal CPXV 
infection in SCID mice  Subcutaneous 
Treatment every three days with CDV (100 mg/kg) through day 30 of the infection resulted in significant delay in 
the time of death but final mortality  [101] 
Treatment with CDV at 100 mg/kg/dose starting on day 0 and repeating the dose every three days resulted in delay 
of time of death but not in protection from lethal infection.  [100] 
Cutaneous CPXV 
infection in hairless mice  Intraperitoneal   Hairless mice treated with 50 mg/kg beginning +24 h after viral inoculation, 3 weekly for one week, had 
significantly reduced lesion-day AUCs (area under the curve) and mean peak lesion scores. 
[112] 
Cutaneous VACV 
infection in hairless mice 
or athymic nude mice 
Intraperitoneal / 
topical 
Hairless mice treated with 50 mg/kg of CDV (starting 24 h post-inoculation of the virus once a day for seven days) 
or topically with 5% CDV 3 a day for seven days) had a significantly lower lesion-day AUCs (area under the 
curve) and mean peak lesion scores. 
[112] 
Topical treatment with 1% CDV, initiated at the day of infection or at day 1 p.i. during 5 days, completely protected 
against virus-induced cutaneous lesions and against associated mortality. Systemic treatment with CDV (100 mg/kg 
3 or 5 per week initiated at 14 days post-infection caused healing and regression of the lesions. 
[113] 
CDV at 100 mg/kg once a day on days 1 and 2 after infection resulted in protection from lethal infection and 
significant reduction in viral titers in the lungs.  [108] 
Topical treatment with 1%-CDV cream (twice daily for seven days) of immunocompromised mice (hair-less mice 
treated with cyclophosphamide) was much more effective in reducing the severity of primary lesions and the 
number of satellite lesions than was systemic CDV treatment (100 mg/kg/day, given every three days). Both forms 
of treatment delayed death. Topical drug treatment markedly reduced virus titers in the skin and snout, whereas 
systemic treatment did not.  
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Table 1. Cont. 
Animal model  Route of CDV 
administration  Evidence for Efficacy  Reference 
Smallpox vaccine in 
monkeys  Intravenous  Coadministration of CDV (20 mg/kg) and smallpox vaccine reduced vaccination side effects but interfered with 
vaccine-elicited immune responses and immunity.  [44] 
Footpad ECTV 
inoculation in mice  Intraperitoneal 
Mice given 5 mg/kg/dose starting 24 h after infection had mild disease (reduced inflammation and footpad swelling) 
but showed a 100% recovery. Animals receiving higher doses of CDV (20 or 100 mg/kg/day) had mild footpad 
swelling and 100% recovery. 
[115] 
Daily treatment with 100 mg/kg/day CDV for five days starting one day after infection with a mouse interleukin-4 
(producing virus causing host immune dysfunction and severe disease) delayed but could not prevent death from 
systemic infection. 
[115] 
Intranasal ECTV 
inoculation in mice  Intraperitoneal  CDV injection at 5 mg/kg on day zero and at 1.25 mg/kg on day three protected 100% of animals from lethality.  [116] 
Aerosolized MPXV 
infection in monkeys  Intravenous  A single treatment of 5 mg/kg on the day of infection resulted in significantly reduced mortality and completely 
protected the animals from clinically and laboratory signs of disease.  [117] 
Intratracheal MPXV 
infection in monkeys  Intraperitoneal  A dose of CDV of 5 mg/kg every other day for five days or six doses starting one day after infection resulted in 
significantly reduced mortality and reduced numbers of cutaneous monkeypox lesions.  [43] 
Intravenous MPXV 
infection in monkeys  Intravenous  5 mg/kg of CDV given before or up to two days after infection led to complete protection with no signs of illness 
and control of viral replication in blood.  [118–120] 
Intravenous VARV 
infection in monkeys  Intravenous  5 mg/kg of CDV given before or up to two days after infection led to complete protection with no signs of illness 
and control of viral replication in the blood.  [118–120] 
Hind thighs orf virus 
scarification in lambs  Topical 
1% CDV given for four consecutive days resulted in milder lesions that resolved more quickly than untreated 
lesions. The scabs of the treated animals contained significantly lower amounts of viable virus meaning there should 
be less contamination of the environment with virus than would normally occur. 
[42] 
Animals were treated with a paint of 0.5% or 1% CDV + sucralfate 15% (wound healing properties) + NaH2PO4 
16% w/w and with sucralfate gel suspension alone as control. The treatment with formulations containing CDV and 
phosphate salt for four consecutive days resulted in a rapid resolution of the lesions, with scabs containing 
significantly lower amounts of viable virus when compared with untreated lesions and lesions treated with sucralfate 
suspension alone. 
[121] 
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